Skip to content
← Full study record

NCT02255461 · OUTCOME

Single Dose Apparent Volume of Central Compartment (Vc/F)

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors · Source last updated 2021-03-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
L/m^2
Interval / dispersion
Full Range
Time frame
Up to day 3

What was measured

On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.

Analysis population: Patients with blood samples collected for pharmacokinetic studies on days 1-3 of course 1 were included.

Groups in this outcome

Stratum I, Dose Level 1 (50 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum I, Dose Level 2 (75 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum I, Dose Level 3 (95 mg/m2)

Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum II, Dose Level 1 (50 mg/m2)

Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Stratum II, Dose Level 2 (75mg/m2)

Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum I, Dose Level 1 (50 mg/m2)3
Stratum I, Dose Level 2 (75 mg/m2)12
Stratum I, Dose Level 3 (95 mg/m2)6
Stratum II, Dose Level 1 (50 mg/m2)4
Stratum II, Dose Level 2 (75mg/m2)9

Reported measurements

Source class 1
Values in L/m^2 · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Stratum I, Dose Level 1 (50 mg/m2)672Not reported6221189Not reported
Stratum I, Dose Level 2 (75 mg/m2)741Not reported5621856Not reported
Stratum I, Dose Level 3 (95 mg/m2)708Not reported601819Not reported
Stratum II, Dose Level 1 (50 mg/m2)847Not reported3731153Not reported
Stratum II, Dose Level 2 (75mg/m2)850Not reported3983653Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        622
        upper Limit
        1189
        value
        672
      2. group Id
        OG001
        lower Limit
        562
        upper Limit
        1856
        value
        741
      3. group Id
        OG002
        lower Limit
        601
        upper Limit
        819
        value
        708
      4. group Id
        OG003
        lower Limit
        373
        upper Limit
        1153
        value
        847
      5. group Id
        OG004
        lower Limit
        398
        upper Limit
        3653
        value
        850
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      12
    3. group Id
      OG002
      value
      6
    4. group Id
      OG003
      value
      4
    5. group Id
      OG004
      value
      9
    units
    Participants
description
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
dispersion Type
Full Range
groups
  1. description
    Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Stratum I, Dose Level 1 (50 mg/m2)
  2. description
    Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Stratum I, Dose Level 2 (75 mg/m2)
  3. description
    Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG002
    title
    Stratum I, Dose Level 3 (95 mg/m2)
  4. description
    Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG003
    title
    Stratum II, Dose Level 1 (50 mg/m2)
  5. description
    Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG004
    title
    Stratum II, Dose Level 2 (75mg/m2)
param Type
MEDIAN
population Description
Patients with blood samples collected for pharmacokinetic studies on days 1-3 of course 1 were included.
reporting Status
POSTED
time Frame
Up to day 3
title
Single Dose Apparent Volume of Central Compartment (Vc/F)
type
PRIMARY
unit Of Measure
L/m^2

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice